NYSE:LLY - Eli Lilly And Co Stock Price, Price Target & More

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly And Co announced a quarterly dividend on Monday, June 18th. Shareholders of record on Wednesday, August 15th will be given a dividend of $0.5625 per share on Monday, September 10th. This represents a $2.25 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date is Tuesday, August 14th. View Eli Lilly And Co's Dividend History.

Eli Lilly And Co (NYSE:LLY) announced its earnings results on Tuesday, April, 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.21. The business earned $5.70 billion during the quarter, compared to analysts' expectations of $5.51 billion. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The business's revenue was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.98 earnings per share. View Eli Lilly And Co's Earnings History.

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Eli Lilly And Co.

Eli Lilly And Co updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.87. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.43 billion.

19 brokers have issued 12 month price objectives for Eli Lilly And Co's shares. Their predictions range from $78.00 to $115.00. On average, they expect Eli Lilly And Co's stock price to reach $94.2941 in the next year. This suggests a possible upside of 5.9% from the stock's current price. View Analyst Ratings for Eli Lilly And Co.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly And Co in the last year. There are currently 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Media coverage about LLY stock has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eli Lilly And Co earned a news impact score of 0.13 on Accern's scale. They also assigned media coverage about the company an impact score of 43.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Eli Lilly And Co's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.24%), Bank of Montreal Can (0.38%), Fisher Asset Management LLC (0.34%), Hexavest Inc. (0.12%), DnB Asset Management AS (0.09%) and NN Investment Partners Holdings N.V. (0.08%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

LLY stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., Bank of Montreal Can, NN Investment Partners Holdings N.V., Hexavest Inc., State of Alaska Department of Revenue, Atria Investments LLC, Rathbone Brothers plc and Gateway Investment Advisers LLC. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.

LLY stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Fisher Asset Management LLC, Manning & Napier Group LLC, Farmers Trust Co., Park National Corp OH, Private Asset Management Inc., IFM Investors Pty Ltd and Gulf International Bank UK Ltd. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LLY stock can currently be purchased for approximately $89.01.

Eli Lilly And Co has a market capitalization of $97.37 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]